

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津發展控股有限公司
TIANJIN DEVELOPMENT HOLDINGS LIMITED

(Incorporated in Hong Kong with limited liability)

(Stock Code: 882)

UNAUDITED FINANCIAL RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2021 OF TIANJIN LISHENG PHARMACEUTICAL CO., LTD.

This announcement is made by Tianjin Development Holdings Limited (the “**Company**”) pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited to provide shareholders of the Company and the public with the unaudited consolidated financial results of its indirect non-wholly owned subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (天津力生製藥股份有限公司) (“**Lisheng Pharmaceutical**”), for the nine months ended 30 September 2021.

Lisheng Pharmaceutical is a company incorporated in the People’s Republic of China whose shares are listed on the Shenzhen Stock Exchange. As at the date of this announcement, the Company indirectly holds approximately 34.41% of the issued share capital of Lisheng Pharmaceutical. The unaudited consolidated income statement for the nine months ended 30 September 2021 and the unaudited condensed consolidated balance sheet as at 30 September 2021 of Lisheng Pharmaceutical prepared in accordance with China Accounting Standards for Business Enterprises are provided below:

Tianjin Lisheng Pharmaceutical Co., Ltd.
Consolidated Income Statement
For the nine months ended 30 September 2021

	For the nine months ended 30 September	
	2021	2020
	RMB	RMB
	(unaudited)	(unaudited)
1. Total operating income	835,659,085.18	915,432,733.22
Including: Operating income	835,659,085.18	915,432,733.22
2. Total operating costs	732,113,052.47	832,338,897.02
Including: Costs of sales	349,599,174.42	338,574,215.61
Business tax and surcharge	16,718,823.34	18,408,113.46
Selling expenses	264,030,291.51	359,505,431.31
Administrative expenses	78,988,831.68	83,000,800.49
Research expenses	78,976,396.77	58,660,220.84
Finance expenses	-56,200,465.25	-25,809,884.69
Including: Interest expenses	270,800.91	641,273.68
Interest income	56,589,493.54	26,639,894.19
Add: Other gains	3,840,908.60	4,711,549.98
Investment income	11,488,646.51	8,026,974.32
Including: Investment income from associates and joint ventures	7,788,146.51	6,524,605.49
Income from change in fair value	700,770.00	—
Impairment losses on credit	31,051.72	-13,562.04
3. Operating profit	119,607,409.54	95,818,798.46
Add: Non-operating income	323,276.96	990,493.04
Less: Non-operating expenses	311,613.36	353,675.66
4. Total profit	119,619,073.14	96,455,615.84
Less: Income tax expenses	21,902,087.87	17,286,463.31
5. Net profit	97,716,985.27	79,169,152.53
Net profit attributable to owners of parent company	97,716,985.27	79,169,152.53
6. Other comprehensive income, net of tax	—	—
7. Total comprehensive income	97,716,985.27	79,169,152.53
Total comprehensive income attributable to owners of parent company	97,716,985.27	79,169,152.53
8. Earnings per share:		
(1) Basic earnings per share (RMB/share)	0.54	0.43
(2) Diluted earnings per share (RMB/share)	0.54	0.43

Tianjin Lisheng Pharmaceutical Co., Ltd.
Condensed Consolidated Balance Sheet
As at 30 September 2021

	At 30 September 2021 RMB (unaudited)	At 31 December 2020 RMB (audited)
ASSETS		
Current assets	2,276,528,514.47	2,244,370,080.04
Non-current assets	<u>2,804,039,105.47</u>	<u>2,777,812,908.95</u>
Total assets	<u><u>5,080,567,619.94</u></u>	<u><u>5,022,182,988.99</u></u>
LIABILITIES		
Current liabilities	477,101,356.57	502,759,834.78
Non-current liabilities	<u>222,984,359.04</u>	<u>217,327,396.52</u>
Total liabilities	<u><u>700,085,715.61</u></u>	<u><u>720,087,231.30</u></u>
OWNERS' EQUITY		
Share capital	182,454,992.00	182,454,992.00
Capital reserves	1,691,564,108.23	1,691,564,108.23
Other comprehensive income	1,005,189,102.53	1,005,189,102.53
Special reserves	13,690,479.72	14,775,819.15
Surplus reserves	402,847,934.45	402,847,934.45
Undistributed profit	<u>1,084,735,287.40</u>	<u>1,005,263,801.33</u>
Total equity attributable to owners of parent company	<u><u>4,380,481,904.33</u></u>	<u><u>4,302,095,757.69</u></u>
TOTAL OWNERS' EQUITY	<u><u>4,380,481,904.33</u></u>	<u><u>4,302,095,757.69</u></u>
TOTAL LIABILITIES AND OWNERS' EQUITY	<u><u>5,080,567,619.94</u></u>	<u><u>5,022,182,988.99</u></u>

Shareholders of the Company should note that the above unaudited financial information pertains only to Lisheng Pharmaceutical and not to the Company itself.

Details of the unaudited consolidated financial results of Lisheng Pharmaceutical for the nine months ended 30 September 2021 are available on the website of Shenzhen Stock Exchange (www.szse.cn).

By Order of the Board
Tianjin Development Holdings Limited
Chen Yanhua
Executive Director and General Manager

Hong Kong, 25 October 2021

As at the date of this announcement, the board of directors of the Company consists of Mr. Zhang Bingjun, Mr. Chen Yanhua, Dr. Li Xiaoguang, Mr. Zhuang Qifei, Mr. Cui Xiaofei, Mr. Cheung Wing Yui, Edward, Dr. Cheng Hon Kwan**, Mr. Mak Kwai Wing, Alexander**, Ms. Ng Yi Kum, Estella**, Mr. Wong Shiu Hoi, Peter** and Dr. Loke Yu**.*

* *non-executive director*

** *independent non-executive director*